Clinical significance of FBXW7 loss of function in human cancers

Table 5 FBXW7 potential inducers

Combining regions	Drug	Drug Research PhaseDrug Investigation Phase	Action
148878-148938	Troleandomycin	approved	inducer
	Dexamethasone	approved, investigational, vet_approved	inducer
	Rifampicin	approved	inducer
	Midostaurin	approved, investigational	inducer
	Dexamethasone acetate	approved, investigational, vet_approved	inducer
	Myrrh	approved	inducer
	Brigatinib	approved, investigational	inducer
	Rifapentine	approved, investigational	inducer
	Prednisone	approved, vet_approved	inducer
	Methylprednisolone	approved, vet_approved	inducer
	Lemborexant	approved, investigational	inhibitor/inducer
	Prednisolone phosphate	approved, vet_approved	inducer
	Relugolix	approved, investigational	inducer
	Ursodeoxycholic acid	approved, investigational	inducer

Potential inducers for FBXW7 based on DrugBank database prediction tool, screened based on the sequences of FBXW7 in GeneBank. According to the database, “The term “inducer” can be a drug or chemical that typically serves to induce or trigger the appropriate gene transcription necessary to synthesize new copies of a particular enzyme, in addition to what quantity may already be present for that enzyme in the body” (https://www.drugbank.com/)

ISSN: 1476-4598